New Faster-Acting Prostate Cancer Drug Hailed As “Significant Advance” In Improving Quality Of Life For Patients, UK
FIRMAGON® (degarelix) a new fast-acting hormone treatment for advanced prostate cancer is being offically launched in the UK yesterday at the British Association of Urological Surgeons Annual Meeting in Glasgow. Prostate cancer is the most common cancer in men, and over 35,000 cases a year (1) are diagnosed in the UK , with 10,239 men dying in 2007.(2) Prostate cancer is fuelled by the male hormone testosterone.
More: continued here
Filed under: Prostate on June 30th, 2009
You must be logged in to post a comment.